Eli Lilly launches new version of weight-loss drug Zepbound: a single dose covers a whole month
Show original
For self-paying patients, the starting price for the entry-level dose on Lilly's direct sales platform, LillyDirect, is only $299 per month. With the explosive growth of Zepbound, Lilly has captured the majority of the weight loss drug market from its competitor Novo Nordisk. In the fourth quarter, Zepbound's revenue in the US reached $4.2 billions, a year-on-year surge of 122%. The US Food and Drug Administration (FDA) has approved the label expansion for Zepbound, incorporating this multi-dose device.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Humanoid robots enter BMW factory, with Swedish company Hexagon as partner
华尔街见闻•2026/02/28 16:17
Analysis: Ethereum MVRV indicator shows the price is already in a long-term bottom range
Chaincatcher•2026/02/28 15:52
Trending news
MoreCrypto prices
MoreBitcoin
BTC
$65,062.76
-1.01%
Ethereum
ETH
$1,904.76
-1.41%
Tether USDt
USDT
$1
-0.01%
BNB
BNB
$604.14
-1.29%
XRP
XRP
$1.33
-1.95%
USDC
USDC
$1
-0.01%
Solana
SOL
$81.16
-0.54%
TRON
TRX
$0.2805
-0.93%
Dogecoin
DOGE
$0.09099
-3.10%
Cardano
ADA
$0.2688
-3.43%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now